Sign in Sign up for free

Neovacs S.A Revenue Q/Q

What is the Revenue Q/Q of Neovacs S.A?

The Revenue Q/Q of Neovacs S.A. is 104.00%

What is the definition of Revenue Q/Q?

Quarterly revenue growth, year over year, is the increase of a company’s revenue compared to the performance in the corresponding quarter of a previous year expressed as a percentage.

quarterly growth yoy (year over year)

Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.

Revenue Q/Q of companies in the Health Care sector on EURONEXT compared to Neovacs S.A

What does Neovacs S.A do?

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Companies with revenue q/q similar to Neovacs S.A